Relationship between clinical and morphological parameters and survival in non-small cell lung cancer with protein expression and gene HER2-neu amplification
- Authors: Kobyakov D.S.1, Avdalyan A.M2, Lazarev A.F2, Lushnikova E.L3, Nepomnyaschikh L.M3
-
Affiliations:
- Kogalymskaya City Hospital
- N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical Sciences
- Research Institute of Regional Pathology and Pathomorphology Siberian Department RAMS
- Issue: Vol 19, No 5 (2014)
- Pages: 31-36
- Section: Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/40105
- DOI: https://doi.org/10.17816/onco40105
- ID: 40105
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Dmitriy S. Kobyakov
Kogalymskaya City Hospital
Email: dskob@yandex.ru
MD, PhD 628481, Kogalym, Russian Federation
A. M Avdalyan
N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical SciencesAltai branch 656049, Barnaul, Russian Federation
A. F Lazarev
N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical SciencesAltai branch 656049, Barnaul, Russian Federation
E. L Lushnikova
Research Institute of Regional Pathology and Pathomorphology Siberian Department RAMS630117, Novosibirsk, Russian Federation
L. M Nepomnyaschikh
Research Institute of Regional Pathology and Pathomorphology Siberian Department RAMS630117, Novosibirsk, Russian Federation
References
- Reinmuth N., Brandt B., Kunze W.P., Junker K., Thomas M., Achatzy R. et al. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur. Respir. J. 2000; 16: 991-6.
- Hofmann M., Stoss O., Shi D., Buttner R., van de Vijver M., Kim W. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.
- Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A. et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer. Res. 1999; 5: 1966-75.
- Au N.H., Cheang M., Huntsman D.G., Yorida E., Coldman A., Elliott W.M. et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J. Pathol. 2004; 204: 101-9.
- Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I. , Bartolini S., Ceresoli G.L. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005; 23: 5007-18.
- Cox G., Vyberg M., Melgaard B., Askaa J., Oster A., O’Byme K.J. Herceptest: HER2 expression and gene amplification in nonsmall cell lung cancer. Int. J. Cancer. 2001; 92: 480-3.
- Grob T.J., Kannengiesser I., Tsourlakis M.C., Atanackovic D. , Koenig A.M., Vashist Y.K. et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod. Pathol. 2012; 25: 1566-73.
- Hirashima N., Takahashi W., Yoshii S., Yamane T., Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod. Pathol. 2001; 14: 556-62.
- Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B. et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 2002; 86: 1449-56.
- Hsieh C.C., Chow K.C., Fahn H.J., Tsai C.M., Li W.Y., Huang M.H. et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann. Thorac. Surg. 1998; 66: 1159-64.
- Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer. 2003; 103: 61-6.
- Pelosi G., Del Curto B., Dell’Orto P., Pasini F., Veronesi G., Spaggiari L. et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int. J. Cancer. 2005; 113: 101-8.
- Tan D., Deeb G., Wang J., Slocum H.K., Winston J., Wiseman S. et al. HER-2/neu protein expression and gene alteration in stage I-IIIA nonsmall-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003; 12: 201-11.
- Liu L., Shao X., Gao W., Bai J., Wang R., Huang P. et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J. Thorac. Oncol. 2010; 5: 1922-32.
- Sobin L., Gospodarowicz M., Wittekind C. (Eds.): TNM Classification of Malignant Tumours. 7th Ed. Oxford: Wiley-Blackwell, 2009: 138-46.
- Wang S., Hossein Saboorian M., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S. et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002; 15: 137-45.
- Panagiotou I., Georgiannos S.N., Tsiambas E., Karameris A., Konstantinou M., Lazaris A.C. et al. Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior. Asian Pac. J. Cancer. Prev. 2012; 13: 6311-8.
- Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L.V., Botta C., Pasini B. et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219: 16-24.
- Ma J., Gao M., Lu Y., Feng X., Zhang J., Lin D. et al. Gain of 1q25-32, 12q23-24.3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer. J. Pathol. 2006; 210: 205-13.
- Onchi H., Hirose K., Yamaguchi A., Noriki S., Fukuda M. Prognostic value of numerical aberrations of chromosome 17 in differentiated gastric cancer: evaluation by multivariate regression analysis. Oncol. Rep. 2000; 7: 1317-22.
- Yoon H.H., Shi Q., Sukov W.R., Lewis M.A., Sattler C.A., Wiktor A.E. et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J. Clin. Oncol. 2012; 30: 3932-8.
- Vanden Bempt I., Van Loo P., Drijkoningen M., Neven P., Smeets A, Christiaens M.R. et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J. Clin. Oncol. 2008; 26: 4869-74.